findmyKOL

Benjamin Xu, MD

Enriched profile

Assistant Professor of Clinical Ophthalmology, University of Southern California · Keck School of Medicine of USC

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Los Angeles, CA · West · United StatesSpecialtyOphthalmologyFocusGlaucoma and retinal disorders+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceNone verifiedPayments2021–2025NIH funding2019–2026

Benjamin Xu is Assistant Professor of Clinical Ophthalmology, University of Southern California at Keck School of Medicine of USC. OpenAlex indexes 166 publications with 2,104 citations (h-index 26); ClinicalTrials.gov lists 1 registered study with this person as an investigator.

Data verified 23 Oct 2026

Overview

Updated 24 Oct 2026

Benjamin Xu, M.D., PH.D., is Assistant Professor of Clinical Ophthalmology, University of Southern California at Keck School of Medicine of USC. The public record shows 166 publications with 2,104 citations (h-index 26), centered on Glaucoma and retinal disorders, Corneal surgery and disorders, Retinal Imaging and Analysis. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 21 companies, 3 NIH-funded awards (2019–2026).

  • Most recent indexed publication: 2026 · The British journal of ophthalmology
  • Top research focus: Glaucoma and retinal disorders
  • 1 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 21 companies

Generated from the cited public record · current as of 24 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Glaucoma1 trialComa1 trialMacular Degeneration (AMD)

Research focus

OpenAlex concept fingerprint
Glaucoma and retinal disordersCorneal surgery and disordersRetinal Imaging and AnalysisRetinal Diseases and TreatmentsIntraocular Surgery and Lenses

Drugs & molecules

across trials, industry payments and publications
Durystageneric · BimatoprostClinical trials—Industry payments11Publications—Vuitygeneric · PilocarpineClinical trials—Industry payments3Publications—Ozurdexgeneric · DexamethasoneClinical trials—Industry payments2Publications—CyclosporineClinical trials—Industry payments1Publications—Eyleageneric · AfliberceptClinical trials—Industry payments1Publications—IDoseTRClinical trials—Industry payments1Publications—Loteprednol etabonateClinical trials—Industry payments1Publications—Oxervategeneric · CenegerminClinical trials—Industry payments1Publications—Prolensageneric · BromfenacClinical trials—Industry payments1Publications—Vyzultageneric · Latanoprostene bunodClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Abbvie Inc.Clinical trials—Industry payments35Allergan, Inc.Clinical trials—Industry payments20Alcon Vision LLCClinical trials—Industry payments12Heidelberg Engineering, Inc.Clinical trials—Industry payments9Boston Scientific CorporationClinical trials—Industry payments6Glaukos CorporationClinical trials—Industry payments6Johnson & Johnson Surgical Vision, Inc.Clinical trials—Industry payments5Sight Sciences, Inc.Clinical trials—Industry payments4Alcon Research LLCClinical trials—Industry payments3New World Medical,Inc.Clinical trials—Industry payments2Bausch & Lomb Americas Inc.Clinical trials—Industry payments1Bausch & Lomb, a division of Bausch Health US, LLCClinical trials—Industry payments1Carl Zeiss Meditec, Inc.Clinical trials—Industry payments1Dompe US, Inc.Clinical trials—Industry payments1Nova Eye, Inc.Clinical trials—Industry payments1Ocular Therapeutix, Inc.Clinical trials—Industry payments1Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments1Stryker CorporationClinical trials—Industry payments1Topcon Medical Systems, Inc.Clinical trials—Industry payments1University of California, San DiegoClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
166publications

Distinct works indexed by OpenAlex, matched via ORCID; 9 in PubMed.

2,104citations

Total citations across indexed works.

26h-index

Hirsch index (OpenAlex). i10-index 58.

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
21companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
3NIH grants · 2019–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 24 Oct 2026

Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:

Industry payments

Updated 24 Oct 2026

21 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    92.9%
    Prostaglandin Analog47.2%
    Latanoprost82%Lumigan9%Tafluprost5%Travoprost3%Zioptan1%
    Part D<11 patients
    Carbonic Anhydrase Inhibitor25%
    Dorzolamide-Timolol55%Dorzolamide Hcl17%Acetazolamide9%Brinzolamide7%Azopt7%Simbrinza5%
    Part D<11 patients

    + 4 more classes in this area

  • Cardiovascular

    5.6%
    Beta blocker5.6%
    Timolol Maleate100%
    Part D≥44 patients
  • Musculoskeletal

    0.8%
    Cyclooxygenase Inhibitor0.8%
    Ketorolac Tromethamine100%
    Part D≥12 patients
All 4 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)42.6% facility · 57.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 24 Oct 2026

3 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:

Congress activity

Updated 24 Oct 2026

2 congress contributions (2022–2024) across AACR per OpenAlex. The most recent:

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 24 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 24 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Rohit Varma44Bruce S. Burkemper34Anmol A. Pardeshi34Grace M. Richter33Brandon J. Wong24Galo Apolo22Roberta McKean‐Cowdin20Brian C. Toy19Xuejuan Jiang18Brian J. Song18Kyle A. Bolo17Zhongdi Chu16Ruikang K. Wang16Tin Aung14Khristina I. Lung14Robert Neal Weinreb13Mina Torres13Vivian H. LeTran11David Steven Friedman11Alex S. Huang10Kristy G. Yoo10L. Jiun10Paul J. Foster10Sally L. Baxter10Mingguang He9Dominic Joseph Grisafe9Jae Chang Lee9Sasan Moghimi8Seth A. Seabury8Austin Cho8Sophia Ying Wang7Lauren Patty Daskivich7Jing Shan7Ryuna Chang7Abe E. Song7William S. Gange7Carl Kesselman7Xiao Zhou7Yuzhen Jiang6Michael Vincent Boland6

Online presence

Updated 24 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • Other

    profiles.sc-ctsi.org/benjamin.xu

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.sc-ctsi.org ↗
  • Other

    keckmedicine.org

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →keckmedicine.org ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 24 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    PhD, Columbia University, 2012 (Neuroscience)

    2012
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.sc-ctsi.org ↗
  • Doctor of Medicine

    Columbia University in the City of New York

    2012
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →keckmedicine.org ↗

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.